You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Veracyte reported total Q3 revenues of $31.1 million compared to $31.0 million in Q3 2019, beating analysts' average of $23.9 million.
The team published data on Monday highlighting its microfluidic chip's ability to help predict the clinical outcomes of glioblastoma patients.
Ambry will provide RNA sequencing for Scipher's PrismRA blood test to predict response to TNF inhibitor therapies in rheumatoid arthritis patients.
In its IPO prospectus, the company shared plans to broaden the use of its methylation technology from cancer screening to diagnostics and residual disease monitoring.
Carlsbad, California-based BioSpyder said that HTG has repeatedly and baselessly accused it of infringing HTG's patent for quantitative nuclease protection assay and sequencing improvements.
Caris will sequence DNA and RNA for certain cancer patients and potentially help Merus enroll cancer patients with NRG1 fusions in the Phase I/II eNRGy trial for zenocutuzumab.
FBB Biomed, cofounded by a diagnostics industry veteran, is attempting to develop a blood RNA test to predict COVID-19 disease severity.
The firm has collected important health economic evidence for its clinical lung cancer assay and is building evidence for other products in additional cancer types.
Lexogen did not disclose the funding amount, but said it was one of €16 million ($17.4 million) in awards from the Austria Research Promotion Agency.
If the results are validated, investigators believe the method could help diagnose patients without the need for a needle biopsy and with fewer false positives.